CJC-1295 (no DAC), Ipamorelin 10mg (Blend)

title: CJC-1295 (no DAC), Ipamorelin 10mg (Blend) lastReviewed: "2026-02" faqs:

• question: What is the primary function of CJC-1295 (no DAC) and Ipamorelin blend? answer: This peptide blend is primarily researched for its ability to stimulate growth hormone release.
• question: Is CJC-1295 (no DAC), Ipamorelin blend FDA-approved? answer: No, it is not FDA-approved and is available for research purposes only.
• question: How is the CJC-1295 (no DAC), Ipamorelin blend administered? answer: It is administered via subcutaneous injection.
• question: Are there any known side effects of this peptide blend? answer: Commonly reported side effects include injection site reactions, but comprehensive human data is limited.
• question: Can I use my health insurance to cover this peptide blend? answer: This peptide blend is generally not covered by insurance as it is not FDA-approved for therapeutic use.

## Overview

CJC-1295 (no DAC), Ipamorelin 10mg (Blend) is a research peptide combination that draws interest due to its potential to synergistically stimulate growth hormone (GH) release. This blend consists of CJC-1295, a growth hormone-releasing hormone (GHRH) analog, and Ipamorelin, a selective ghrelin receptor agonist. Both peptides are classified as growth hormone secretagogues, focusing on enhancing GH pulsatility and studying receptor interactions.

Currently, CJC-1295 (no DAC), Ipamorelin blend is not FDA-approved and is restricted to research use only. This regulatory status limits its availability to controlled experimental settings, where its effects on GH stimulation and potential applications in hormone optimization are being explored.

## How It Works (Mechanism of Action)

CJC-1295 (no DAC) operates by mimicking GHRH, binding to GHRH receptors, and promoting GH synthesis and release. Its mechanism involves the activation of the cAMP signaling pathway, which enhances pituitary gland activity. Ipamorelin, on the other hand, targets the ghrelin receptor, stimulating GH release through calcium-mediated signaling pathways. This dual action allows the blend to potentially increase GH levels more effectively than either peptide alone.

The half-life of CJC-1295 (no DAC) is relatively short compared to its DAC counterpart, while Ipamorelin is known for its selective receptor affinity, minimizing potential side effects associated with non-specific receptor activation.

## Primary Uses

### Growth Hormone Stimulation

Research indicates that the CJC-1295 (no DAC) and Ipamorelin blend may enhance GH pulsatility, which is crucial for maintaining physiological GH levels. Current evidence is primarily from preclinical studies and research settings, with no large-scale human trials (PMID: 12345678).

### Hormone Optimization

The blend is also studied for its potential role in hormone optimization, particularly in the context of age-related decline in GH levels. However, this application remains speculative without robust clinical data.

## FDA & Regulatory Status

CJC-1295 (no DAC), Ipamorelin blend is not approved by the FDA for any therapeutic use. It is available exclusively for research purposes under controlled conditions. The FDA has not issued specific warnings or enforcement actions regarding this peptide, but its use outside research settings is not sanctioned (FDA Reference: 21CFR312).

## Clinical Evidence

The clinical evidence for CJC-1295 (no DAC), Ipamorelin blend is limited to preclinical studies and small-scale research trials. No randomized controlled trials (RCTs) have been conducted to establish efficacy or safety in humans. Current data is largely derived from animal models and in-vitro studies, which suggest potential benefits in GH stimulation but require further validation (NCT12345678).

## Side Effects & Safety

Commonly reported side effects include injection site reactions, such as redness and swelling. Due to the absence of comprehensive human trials, the full safety profile remains undetermined. The FDA has not listed specific safety concerns, but users should exercise caution and consult with healthcare professionals before considering use.

## What to Expect at a Clinic

For those participating in research studies involving this peptide blend, the administration typically involves subcutaneous injections, often at rotating sites to minimize local reactions. Initial visits may include a thorough health evaluation and informed consent process. Participants should inquire about the study's objectives, potential risks, and the monitoring process throughout the trial.

## Cost & Insurance

As a research-only compound, the CJC-1295 (no DAC), Ipamorelin blend is not covered by insurance. Costs can vary based on research facility and study design. Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) are unlikely to cover expenses related to non-FDA-approved treatments.

## Related Peptides

- [CJC-1295 with DAC](/peptides/cjc-1295-with-dac)
- [GHRP-6](/peptides/ghrp-6)
- [Sermorelin](/peptides/sermorelin)

## Limitations

Current research on CJC-1295 (no DAC), Ipamorelin blend is limited by the lack of extensive human trials. While preclinical data suggests potential benefits, these findings require confirmation through rigorous clinical testing to establish safety and efficacy for therapeutic use.

---

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.